Angiogenese-Hemmung durch Proteine, Peptide und «small molecules»: Klinischer Einsatz

Publisher： Karger

E-ISSN： 2296-5262|28|4|29-34

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.28, Iss.4, 2005-10, pp. : 29-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Grenzen und Fallen klinischer Studien in der Onkologie

By  

Oncology Research and Treatment, Vol. 31, Iss. 2, 2008-05 ,pp. : 67-71

Karger

Access to resources Recommend Favorite

Planung und Durchführung klinischer Phase-II-Studien

By  

Oncology Research and Treatment, Vol. 31, Iss. 2, 2008-05 ,pp. : 46-52

Karger

Access to resources Recommend Favorite

Planung und Durchführung klinischer Phase-III-Studien

By  

Oncology Research and Treatment, Vol. 31, Iss. 2, 2008-05 ,pp. : 53-57

Karger

Access to resources Recommend Favorite

Planung und Durchführung klinischer Phase-I-Studien

By  

Oncology Research and Treatment, Vol. 31, Iss. 2, 2008-05 ,pp. : 39-45

Karger

Access to resources Recommend Favorite

EGF-Rezeptorblockade mit monoklonalen Antikörpern und so genannten «small molecules»

By  

Oncology Research and Treatment, Vol. 28, Iss. 4, 2005-10 ,pp. : 18-24

Karger

Access to resources Recommend Favorite